Targeting underlying cause of PAH, Cambridge spinout Morphogen-IX raises about $23M in Series B
Back in the year 2000, a major mutation in familial pulmonary arterial hypertension (PAH) was discovered in the receptor for BMP9 — and for years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
